Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Shares Outstanding (2023 - 2025)

Kura Oncology (KURA) has disclosed Shares Outstanding for 3 consecutive years, with $87.9 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 12.3% to $87.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $87.9 million through Dec 2025, up 12.3% year-over-year, with the annual reading at $87.9 million for FY2025, 12.3% up from the prior year.
  • Shares Outstanding for Q4 2025 was $87.9 million at Kura Oncology, up from $87.0 million in the prior quarter.
  • The five-year high for Shares Outstanding was $87.9 million in Q4 2025, with the low at $68.4 million in Q1 2023.
  • Average Shares Outstanding over 3 years is $78.5 million, with a median of $77.1 million recorded in 2024.
  • The sharpest move saw Shares Outstanding grew 3.07% in 2024, then grew 13.58% in 2025.
  • Over 3 years, Shares Outstanding stood at $74.4 million in 2023, then increased by 5.22% to $78.2 million in 2024, then increased by 12.3% to $87.9 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $87.9 million, $87.0 million, and $86.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.